MX377674B - Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada. - Google Patents

Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.

Info

Publication number
MX377674B
MX377674B MX2014011167A MX2014011167A MX377674B MX 377674 B MX377674 B MX 377674B MX 2014011167 A MX2014011167 A MX 2014011167A MX 2014011167 A MX2014011167 A MX 2014011167A MX 377674 B MX377674 B MX 377674B
Authority
MX
Mexico
Prior art keywords
release
rosuvastatin
metformin
immediate
extended
Prior art date
Application number
MX2014011167A
Other languages
English (en)
Other versions
MX2014011167A (es
Inventor
Marie Charmaine Dias
Original Assignee
Althera Life Sciencies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Althera Life Sciencies Llc filed Critical Althera Life Sciencies Llc
Publication of MX2014011167A publication Critical patent/MX2014011167A/es
Publication of MX377674B publication Critical patent/MX377674B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a un producto de dosificación sólida cuya formulación contenga una combinación fija de rosuvastatina y metformina, de tal manera que la rosuvastatina llegue inmediatamente al paciente y la metformina llegue de forma prolongada por un periodo de tiempo, también descrito como liberación prolongada, así como también a los métodos de hacer que tales formas de dosificación sólida y el uso de la forma de dosis de la invención en el tratamiento de pacientes con una combinación fija de formas de dosificación sólida de liberación inmediata de rosuvastatina y liberación prolongada de metformina.
MX2014011167A 2012-03-19 2013-03-15 Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada. MX377674B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612563P 2012-03-19 2012-03-19
US201261640971P 2012-05-01 2012-05-01
PCT/US2013/031986 WO2013142314A1 (en) 2012-03-19 2013-03-15 Oral tablet formulation consisting of immediate release rosuv astatin and extended release metformin

Publications (2)

Publication Number Publication Date
MX2014011167A MX2014011167A (es) 2014-11-14
MX377674B true MX377674B (es) 2025-03-11

Family

ID=49223247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011167A MX377674B (es) 2012-03-19 2013-03-15 Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.

Country Status (3)

Country Link
EP (1) EP2844067A4 (es)
MX (1) MX377674B (es)
WO (1) WO2013142314A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CA2600736A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP5662475B2 (ja) * 2009-12-30 2015-01-28 ビーシーワールド ファーム． カンパニー リミテッド メトホルミン及びロスバスチンを含む医薬組成物

Also Published As

Publication number Publication date
MX2014011167A (es) 2014-11-14
EP2844067A1 (en) 2015-03-11
WO2013142314A1 (en) 2013-09-26
EP2844067A4 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
EA201991484A1 (ru) Лекарственные формы энзалутамида
TN2015000278A1 (en) Autotaxin inhibitors
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
PH12017500453A1 (en) Spirocyclic inhibitors of cathepsin c
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
MX2015004362A (es) Derivados de ketamina.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
PH12016502353A1 (en) Pharmaceutical composition
PH12016502352A1 (en) Pharmaceutical composition
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
IN2013MU03847A (es)
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
ZA201906153B (en) Pharmaceutical compositions for combination therapy
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
MX377674B (es) Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.
MX390789B (es) Composición farmacéutica de dosis fija que comprende mometasona y azelastina.
IN2014DN10683A (es)

Legal Events

Date Code Title Description
FG Grant or registration